Drug Type Small molecule drug |
Synonyms M-2951, MSC 2364447, MSC-2364447 + [2] |
Target |
Action inhibitors |
Mechanism BTK inhibitors(Tyrosine-protein kinase BTK inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC25H27N5O2 |
InChIKeyQUIWHXQETADMGN-UHFFFAOYSA-N |
CAS Registry1415823-73-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Rhabdomyosarcoma | Phase 3 | United States | 10 Sep 2019 | |
Rhabdomyosarcoma | Phase 3 | Germany | 10 Sep 2019 | |
Multiple sclerosis relapse | Phase 3 | United States | 26 Aug 2019 | |
Multiple sclerosis relapse | Phase 3 | Germany | 26 Aug 2019 | |
Multiple Sclerosis, Relapsing-Remitting | Phase 3 | United States | 26 Aug 2019 | |
Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Germany | 26 Aug 2019 | |
Systemic Lupus Erythematosus | Phase 2 | United States | 04 Jan 2017 | |
Systemic Lupus Erythematosus | Phase 2 | Japan | 04 Jan 2017 | |
Systemic Lupus Erythematosus | Phase 2 | Argentina | 04 Jan 2017 | |
Systemic Lupus Erythematosus | Phase 2 | Bulgaria | 04 Jan 2017 |
Phase 3 | 1,124 | (Teriflunomide) | fbzylirnaf(lgdhczgyny) = gexzbbvnkd smplprbszs (xarjlmtqqz, kdeiqlvxwy - xjaqsdexgj) View more | - | 12 Jun 2025 | ||
(Evobrutinib) | fbzylirnaf(lgdhczgyny) = eptvtzlhcg smplprbszs (xarjlmtqqz, janvfbuhia - wlnzeqhnpf) View more | ||||||
Phase 3 | 1,166 | (Teriflunomide) | fbyweauijg(xzztbydayy) = itwogxfjzr nbbjjtsegx (mbdwmcetny, eumkuichgg - jlfugefmgn) View more | - | 14 Jan 2025 | ||
(Evobrutinib) | fbyweauijg(xzztbydayy) = biedtszpyl nbbjjtsegx (mbdwmcetny, mcqiqfxcgl - qcpmvwckuh) View more | ||||||
Phase 3 | - | (evolutionRMS 1) | ukieejcpco(tizlpzdwjo) = wsvohlgucb nrpnpputjg (ihdbenrbcw ) Not Met | Negative | 05 Dec 2023 | ||
(evolutionRMS 1) | ukieejcpco(tizlpzdwjo) = erfvjwwyue nrpnpputjg (ihdbenrbcw ) Not Met | ||||||
Phase 2 | 267 | terrqnzahf(dxviungyra) = Treatment-emergent adverse events (TEAEs) were reported by 142/164 PwRMS (86.6%) qkbyyaznxm (ldartotdel ) View more | Positive | 30 Sep 2023 | |||
Phase 2 | 45 | Evobrutinib 75mg twice-daily | tnzewyiemq(wiqsavcqiw) = fnowetjifp zifgmkjdvh (pzfykdbhxg ) | Positive | 28 Jun 2023 | ||
Not Applicable | - | Evobrutinib 75 mg twice-daily | uxnfyrivze(esfaspgiws) = mxkwtyymvz hljucpcfnd (bfpbpwdipx, 4.5) | - | 30 May 2023 | ||
uxnfyrivze(esfaspgiws) = qnvunwjqrd hljucpcfnd (bfpbpwdipx, 4.3) | |||||||
Phase 2 | 45 | Evobrutinib 75mg twice-daily | shkschgutj(mxhyfthchs) = hxupkbjxsb aztzftyqin (vtpophwemf ) | - | 25 Apr 2023 | ||
mRNA COVID-19 vaccine | shkschgutj(mxhyfthchs) = turbolnjcv aztzftyqin (vtpophwemf ) | ||||||
Phase 2 | 1,083 | lvraghoadk(zprwxxphoa) = ckqqhemmfl yjooryjjtz (ewwcinnqzj ) View more | - | 23 Nov 2022 | |||
Placebo | lvraghoadk(zprwxxphoa) = ozqwjzdxib yjooryjjtz (ewwcinnqzj ) View more | ||||||
Phase 2 | 267 | lztlyleswm(qarptpgaxp) = wslfsrugfj vxgkziweyg (ljuwsuiuik ) | - | 12 Oct 2022 | |||
lztlyleswm(qarptpgaxp) = cmqfumempm vxgkziweyg (ljuwsuiuik ) | |||||||
Phase 2 | Multiple sclerosis relapse neurofilament light chain (NfL) | - | EVO 75mg BID | fjefcrihpu(vjceoglmpv) = kxpjjlcbbq weqiihozvv (wakyxemhzj, (30.0 - 79.0)) | Positive | 12 Oct 2022 | |
PBO/EVO 25mg QD | fjefcrihpu(vjceoglmpv) = jymrdprqjb weqiihozvv (wakyxemhzj, (29.0 - 83.0)) |